Clinical Trial Update: Safety and Intake Effect of EPs® 7630 (an Extract of the Roots of Pelargonium Sidoides) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and intake of EPs 7630, a Pelargonium sidoides root extract, for the common cold; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Cold

Drugs mentioned

• EPs 7630 (Pelargonium sidoides root extract)

Snippet

Sponsor: Dr. Willmar Schwabe GmbH & Co. KG | Conditions: Common Cold | Phase 3 | Status: COMPLETED